
This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
Learn from Prof. Seema Aceves about the interconnectivity of type 2 inflammation and barrier dysfunction in mediating EoE pathophysiology.

Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life
Learn from Dr. Hirano and Dr. Marcon as they discuss how to unmask EoE symptoms that may be hidden by patients' coping mechanisms.
Dr. Dhandapani Ashok highlights treatment options for patients with EoE aged 12 years and younger and the importance of shared decision-making.

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.
In this hypothetical EoE patient case, learn about the different disease domains that are important in seeing the complete patient picture in EoE.

Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.

In this clip from the April WCPD 2025 symposium, Dr Paula Luna discusses how moderate-to-severe AD may hinder growth in pediatric patients.

Explore resources on the importance of partnering with patients to empower them to take an active role in their care.
Join Dr. Nirmala Gonsalves as she reviews symptoms of EoE and tools to assess symptoms in patients with EoE.